INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2 H Einsele; S Parekh; D Madduri; B Santomasso; JG Pérez-Larraya; NWV Donk; B Arnulf; M Mateos; KC Braganca; H Varsos; MJ Carrasco-Alfonso; M Akram; N Lendvai; CC Jackson; Y Olyslager; E Zudaire; C Li; D Geng; A Jakubowiak; A Cohen;

UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN¿DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SZ Usmani; JG Berdeja; A Jakubowiak; M Agha; AD Cohen; D Madduri; P Hari; T Yeh; Y Olyslager; A Banerjee; CC Jackson; A Allred; E Zudaire; W Deraedt; X Wu; L Pacaud; M Akram; Y Lin; T Martin; S Jagannath;

CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: PHASE 3 CARTITUDE-4 SUBGROUP ANALYSIS BY CYTOGENETIC RISK R Mina; B Dhakal; J San-Miguel; N Lendvai; M Vogel; K Li; D Chen; N Patel; H Einsele; J Martinez-Lopez;